The Northern Oncology Research & Development consortium organizes a joint research meeting on the 27th of October 2021 at the Media Docks in Lübeck (also accessible virtual via stream)
Specific genetic alterations present in tumor cells increasingly guide treatment decisions on a single patient level. Under treatment, the amount or clonal composition of genetic alterations in a given tumor may change. So far, we do not make use of this information in a systematic manner. Tumors release cells and nucleic acids, proteins and microvesicles into the circulation that can be detected and quantified using modern technologies. This “liquid biopsy” approach might be a new, noninvasive and efficient way to follow patients’ response to treatment, to predict relapse and to depict changes in clonal composition of the disease. This dynamic information will impact treatment and might constitute a novel toolbox of predictive and prognostic biomarkers to direct necessary treatment to the patients that will need it. New methodology and concepts are emerging and will be available for cancer patients.
This joint research meeting is organized to discuss with clinicians and scientists how liquid biopsy might change cancer patients’ care management.
Due to the current containment regulations and the hygiene and security concept, the number of participants is unfortunately limited and the option for on-site participation will be considered in the order of registration. There is no limit to virtual participation!